论文部分内容阅读
目的分析瑞舒伐他汀对不稳定型心绞痛患者冠状动脉支架植入术后的心肌保护作用。方法选择2014年1月~2016年5月陕西省核215医院收治的择期行冠状动脉支架植入术的不稳定型心绞痛患者90例为研究对象,根据入院治疗病例号顺序分为观察组和对照组,每组45例,对照组在常规治疗的基础之上加用阿托伐他汀,观察组在常规治疗的基础上加用瑞舒伐他汀,比较两组肌酸激酶同工酶(CK-MB)、心肌肌钙蛋白(c Tn I)、人心型脂肪酸结合蛋白(h-FABP)以及超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、干扰素-γ(INF-γ)、白介素-6(IL-6)白介素-10(IL-10)、白介素-18(IL-18)水平。记录两组治疗过程中的药物不良反应及心脏不良事件发生情况。结果术后24 h,两组的CK-MB、c Tn I水平均较术前显著升高(P<0.05),但观察组的CK-MB、c Tn I水平低于对照组(P<0.05),两组h-FABP水平术前术后及组间比较,差异均无统计学意义;术后观察组和对照组的hs-CRP、TNF-α、INF-γ、IL-10、IL-18水平均较术前升高(P<0.05),且对照组的水平均显著高于观察组(P<0.05);术后,观察组的IL-6高于术前,但差异无统计学意义,对照组的IL-6水平显著高于术前和术后观察组(P<0.05)。两组药物不良反应及心脏不良事件发生情况比较,差异无统计学意义。结论与同剂量阿托伐他汀相比,瑞舒伐他汀改善心肌损伤和炎症状态的效果更优,且不增加不良反应。
Objective To investigate the myocardial protective effects of rosuvastatin on patients with unstable angina after coronary stenting. Methods From January 2014 to May 2016, 90 patients with unstable angina pectoris undergoing coronary stent implantation at Nuclear 215 Hospital of Shaanxi Province were enrolled in this study. The patients were divided into observation group and control group Group, with 45 cases in each group. The control group received atorvastatin on the basis of routine treatment. The observation group was given rosuvastatin on the basis of routine treatment. The levels of CK- MB), cTn I, h-FABP, hs-CRP, TNF-α, IFN- (INF-γ), interleukin-6 (IL-6), interleukin-10 (IL-10) and interleukin-18 (IL- Record two groups of treatment of adverse drug reactions and cardiac adverse events. Results The levels of CK-MB and cTnI in both groups were significantly increased 24 h after operation (P <0.05), but the levels of CK-MB and cTn I in the observation group were lower than those in the control group (P <0.05 ), H-FABP levels in the two groups before and after surgery and between groups were not significantly different; postoperative observation group and control group hs-CRP, TNF-α, INF-γ, IL-10, IL- 18 in the observation group was significantly higher than that in the control group (P <0.05), and the levels in the control group were significantly higher than those in the observation group (P <0.05). After the operation, the levels of IL-6 in the observation group were higher than those before the operation Significance, the control group IL-6 levels were significantly higher than the preoperative and postoperative observation group (P <0.05). Two groups of adverse drug reactions and cardiac adverse events, the difference was not statistically significant. Conclusions Rosuvastatin is more effective in improving myocardial injury and inflammatory status than atorvastatin at the same dosage, with no adverse reactions.